| |
| |
|
| Insider
Information: |
Arbuckle Stuart A |
| Relationship: |
Director |
| City: |
Cambridge, |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
62,795 |
|
|
Indirect Shares
|
140 |
|
|
| Direct
Value |
$21,012,430 |
|
|
|
Indirect Value
|
$59,189 |
|
|
| Total
Shares |
62,935 |
|
|
| Total
Value |
$21,071,619 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, COO |
2024-02-26 |
49,691 |
2024-02-26 |
140 |
Premium* |
|
|
Dare Bioscience Inc |
DARE |
Director |
2017-01-03 |
13,104 |
2016-10-03 |
0 |
Premium* |
|
|
Immunogen Inc |
IMGN |
Director |
2024-02-12 |
0 |
2023-06-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
191 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| IMGN |
Immunogen Inc |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,381) |
0 |
0 |
- |
|
| IMGN |
Immunogen Inc |
|
– • – |
2023-06-30 |
4 |
A |
$18.87 |
$13,115 |
D/D |
695 |
4,112 |
0 |
- |
|
| IMGN |
Immunogen Inc |
|
– • – |
2023-09-29 |
4 |
A |
$15.87 |
$13,124 |
D/D |
827 |
4,939 |
0 |
- |
|
| IMGN |
Immunogen Inc |
|
– • – |
2023-12-29 |
4 |
A |
$29.65 |
$13,105 |
D/D |
442 |
5,381 |
0 |
- |
|
| DARE |
Dare Bioscience Inc |
Director |
– • – |
2016-10-03 |
4 |
A |
$1.02 |
$5,750 |
D/D |
5,637 |
5,637 |
0 |
- |
|
| DARE |
Dare Bioscience Inc |
Director |
– • – |
2017-01-03 |
4 |
A |
$0.77 |
$5,750 |
D/D |
7,467 |
13,104 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-08-02 |
4 |
AS |
$177.78 |
$383,116 |
D/D |
(2,155) |
32,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-08-05 |
4 |
AS |
$176.44 |
$274,011 |
D/D |
(1,553) |
32,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-04-15 |
4 |
AS |
$180.95 |
$1,022,148 |
D/D |
(5,624) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-05-02 |
4 |
AS |
$168.56 |
$364,768 |
D/D |
(2,155) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-05-03 |
4 |
AS |
$171.31 |
$226,856 |
D/D |
(1,313) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-05-15 |
4 |
AS |
$165.41 |
$22,000 |
D/D |
(133) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-06-19 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-08-08 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-11-04 |
4 |
AS |
$201.62 |
$747,607 |
D/D |
(3,708) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-11-15 |
4 |
AS |
$205.95 |
$3,913 |
D/D |
(19) |
33,240 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Commercial Officer |
• – – |
2020-01-31 |
4 |
AS |
$238.65 |
$1,119,746 |
D/D |
(4,692) |
33,240 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Commercial Officer |
• – – |
2020-02-03 |
4 |
AS |
$228.90 |
$857,465 |
D/D |
(3,710) |
33,240 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-08-05 |
4 |
OE |
$86.52 |
$134,366 |
D/D |
1,553 |
33,793 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-08-02 |
4 |
OE |
$91.05 |
$196,213 |
D/D |
2,155 |
34,395 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-05-03 |
4 |
AS |
$170.28 |
$40,867 |
D/D |
(240) |
34,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-05-03 |
4 |
OE |
$86.52 |
$134,366 |
D/D |
1,553 |
34,793 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVPChief Commercial Officer |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$330,578 |
D/D |
3,708 |
34,793 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Commercial Officer |
• – – |
2020-02-25 |
4 |
AS |
$229.78 |
$849,418 |
D/D |
(3,634) |
35,179 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Commercial Officer |
• – – |
2020-05-04 |
4 |
AS |
$259.36 |
$404,957 |
D/D |
(1,553) |
35,179 |
0 |
% |
|
191 Records found
|
|
Page 1 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
